Trial Profile
A 156‑week longitudinal observational study of risedronate in preventing vertebral fractures in Japanese patients with established osteoporosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2018
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteopetrosis; Vertebral fracture
- Focus Therapeutic Use
- 03 May 2018 New trial record